NEW research has shed light on why cancer patients choose not to take their prescribed self-administered medications.
Atlantis Health, a leading global patient agency specialising in behavioural science, has revealed key findings from its Global Oncology Patient Nonadherence study.
Three main themes emerged: doubting treatment, reclaiming identity and control, and reducing disruption.
Patients expressed scepticism of the medication's necessity and efficacy, concerns over losing personal identity and control, and difficulties incorporating treatment into their daily lives.
The global study revealed that 56% of participants reported some level of nonadherence to their prescribed anti-cancer medications, mirroring existing research on self-administered oncology treatments.
CEO Jonny Duder said, "these findings are valuable, especially to life sciences companies".
"Together we can provide people living with cancer targeted support for managing their disease and treatment for optimal outcomes."
Additionally, the study assessed engagement with digital health tools, patient organisations, and pharma-sponsored support initiatives.
It also explored how patients perceive their cancer and what motivates them to stick to their medication routines.
To learn more CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Jul 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Jul 24
